Profit From The Biotech Boom With Vectura Group PLC, Hikma Pharmaceuticals Plc And Indivior PLC

Vectura Group PLC (LON:VEC), Hikma Pharmaceuticals Plc (LON:HIK) and Indivior PLC (LON:INDV) are three top plays on the biotech boom.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

After a record-breaking 2014, 2015 is shaping up to be another momentous year for biotech. 

During the first few months of 2015 to the beginning of March, the value of M&A deals in the pharma sector hit $59.3bn, up 94% year on year. Over the past four weeks, at least four more multi-billion dollar deals have been announced. 

And for investors that are looking to play this trend, three of the best picks are Vectura (LSE: VEC), Hikma Pharmaceuticals (LSE: HIK) and Indivior (LSE: INDV). 

In demand 

Early-stage respiratory drug specialist Vectura has struggled to impress over the past five years, but the company is finally starting to show signs of progress. 

The company has sealed a number of deals with key partners over the past 12 months. These include a collaboration deal for the company’s latest asthma product, VR506, signed with an undisclosed US partner. And a global development and licence agreement with Janssen Biotech Inc, a unit of US healthcare group Johnson & Johnson.

What’s more, Vectura has nine products in its pipeline, which are expected to come to market during 2021.  

As Vectura’s deals add up, City analysts expect the group to report a pre-tax profit of £1.6m this year — its first profit for several years. Then, during 2016 and 2017, City analysts expect Vectura’s earnings to take off. Analysts expect the company’s earnings to expand by 200% during 2016 and 260% during 2017.

Generic producer 

Generic drug production is one of the biotech market’s hottest industries. Indeed, as consumers around the world switch to low-cost generic drugs to combat ever-higher medical bills, generic producers have struggled to meet demand.

Hikma is one of the companies that has been able to benefit from this trend. 

Over the past five years Hikma’s earnings have tripled and the company has recently been promoted to the FTSE 100 index. That said, earnings are set to contract by 7% this year, although during 2016, City analysts believe that Hikma’s earnings will rebound by 18%, more than making up for this year’s decline.

Hikma is currently trading at a 2016 P/E of 19.7, compared to the biotech sector average P/E of 31.

Unwanted spin-off

Reckitt Benckiser‘s spin-off Indivior is probably one of the cheapest biotech companies in the world. After failing to find a buyer for Indivior, Reckitt spun the company off at an astonishingly low valuation, due to the fact that Indivior’s sales were coming under pressure from generic competitors.

Unfortunately, City analysts expect the company’s sales to remain under pressure for some time.  Revenue fell 8% during 2014 and is set to fall another 4% this year. Nevertheless, due to these low expectations Indivior is trading at a forward P/E of 14.2, around half the sector’s average valuation. The company is set to offer a dividend yield of 3% this year.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves dose not own any share mentioned here. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£10 a day invested in UK shares could one day create a second income of over £3,000 a month!

Mark David Hartley outlines a strategy he’d use to aim for a second income that gets bigger over time, by…

Read more »

Investing Articles

£20,000 in savings? Here’s how I’d aim to turn that into passive income of £903 a month

Our writer shares one approach to passive income investing, spotlighting a quality FTSE 100 stock he recently added to his…

Read more »

Investing Articles

Great dividend stocks! Here’s the forecast for Associated British Food shares to 2027

Associated British Foods' shares have dropped in value this year. Does this present a dip-buying opportunity for dividend investors to…

Read more »

Investing Articles

Should I sell my FTSE All-Share index fund and buy a S&P 500 tracker instead?

Harvey Jones is wondering whether now is a good time to invest more money in the S&P 500, after a…

Read more »

Investing Articles

Should I buy dirt-cheap BT shares after the recent pullback?

BT shares were on the up but now they're sliding again after the board trimmed full-year guidance. Now Harvey Jones…

Read more »

Investing Articles

Up 28%, can the easyJet share price keep rising?

The easyJet share price has gained altitude over one year but plunged over five. Is now an attractive time for…

Read more »

British Isles on nautical map
Investing Articles

Should I buy more BAE Systems shares at 1,350p?

BAE Systems shares have had a fantastic run since early 2022, yet still don't appear overvalued. Is it now time…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

7% yield and a cheap valuation! Is this one of the best shares to buy this month?

Christopher Ruane has been looking for cheap shares to buy. This one has a 7% dividend yield, so is it…

Read more »